Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbralisib + Obinutuzumab + Chlorambucil in CLL
NCT02100852Phase 1Completed
- Sponsor
- TG Therapeutics, Inc.
- Start
- Mar 2014
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of umbralisib in chronic lymphocytic leukemia (CLL), sponsored by TG Therapeutics, Inc. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Mar 2014; status: completed.
02
Drugs
umbralisib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02100852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02100852.